European Urology Oncology

Slides:



Advertisements
Similar presentations
Charles J. Ryan, M.D., Matthew R. Smith, M.D., Ph.D., Johann S. de Bono, M.B., Ch.B., Ph.D., Arturo Molina, M.D., Christopher J. Logothetis, M.D., Paul.
Advertisements

Volume 69, Issue 5, Pages (May 2016)
Volume 60, Issue 5, Pages (November 2011)
European Urology Focus
Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial)  M. Yoshida, K. Muro, A. Tsuji,
Volume 50, Issue 1, Pages (July 2006)
Volume 65, Issue 6, Pages (June 2014)
Volume 60, Issue 2, Pages (August 2011)
Volume 58, Issue 4, Pages (October 2010)
David Lorente, Karim Fizazi, Christopher Sweeney, Johann S. de Bono 
Volume 69, Issue 5, Pages (May 2016)
Volume 68, Issue 6, Pages e129-e131 (December 2015)
Volume 68, Issue 4, Pages (October 2015)
Volume 66, Issue 5, Pages (November 2014)
European Urology Oncology
Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic.
European Urology Oncology
Volume 69, Issue 5, Pages (May 2016)
Volume 51, Issue 4, Pages (April 2007)
Volume 65, Issue 6, Pages (June 2014)
European Urology Oncology
Managing Nonmetastatic Castration-resistant Prostate Cancer
Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration- resistant Prostate Cancer in the Era of Precision Oncology  Philipp.
European Urology Oncology
Volume 68, Issue 4, Pages (October 2015)
Volume 68, Issue 1, Pages (July 2015)
Volume 74, Issue 1, Pages (July 2018)
Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer  Semini Sumanasuriya, Aurelius Omlin, Andrew Armstrong, Gerhardt Attard, Kim.
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
Volume 66, Issue 3, Pages (September 2014)
Volume 66, Issue 5, Pages (November 2014)
Volume 70, Issue 5, Pages (November 2016)
Volume 69, Issue 4, Pages (April 2016)
Stephen B. Williams, Ashish M
Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers  Pasquale Rescigno, David Lorente, David Dolling, Roberta Ferraldeschi, Daniel.
Volume 72, Issue 1, Pages (July 2017)
Volume 66, Issue 2, Pages (August 2014)
Tyrosine Kinase Inhibitors in Clinical Practice: Patient Selection
Volume 71, Issue 2, Pages (February 2017)
Selma Masic, Janet E. Cowan, Samuel L. Washington, Hao G
European Urology Oncology
European Urology Oncology
Volume 71, Issue 6, Pages (June 2017)
Volume 71, Issue 5, Pages (May 2017)
What's New in Prostate Cancer: Highlights from Urologic and Oncologic Congresses in 2006  Michel Soulié, Nicolas Mottet, Laurent Salomon, Jacques Irani,
Volume 67, Issue 6, Pages (June 2015)
European Urology Oncology
European Urology Oncology
Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy  Matthew Mossanen, Kenneth.
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Cancer  Amar U. Kishan, Rahul.
Volume 74, Issue 3, Pages (September 2018)
European Urology Oncology
Challenges and Opportunities in Hormone-Resistant Prostate Cancer
Volume 71, Issue 4, Pages (April 2017)
Psychotherapeutic Interventions Targeting Prostate Cancer Patients: A Systematic Review of the Literature  Liliana Vartolomei, Shahrokh F. Shariat, Mihai.
Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration- resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary.
Volume 69, Issue 5, Pages (May 2016)
The Cost to Medicare of Bladder Cancer Care
European Urology Oncology
European Association of Urology Guidelines for Systemic Therapy in Metastatic Renal Cell Carcinoma: What is Recommended and Why?  Jean-Jacques Patard 
European Urology Oncology
European Urology Oncology
European Urology Oncology
Oncoforum Urology: Prostate Cancer 2008 at a Glance
European Urology Oncology
European Urology Oncology
Maximilian Burger, Ashish M. Kamat, David McConkey 
Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma  Guillermo de Velasco, Axel Bex, Laurence Albiges, Thomas Powles, Brian.
Morgan Rouprêt, Per-Uno Malmstrom, Peter Black 
Presentation transcript:

European Urology Oncology Cabozantinib for Progressive Metastatic Castration-resistant Prostate Cancer Following Docetaxel: Combined Analysis of Two Phase 3 Trials  Guru P. Sonpavde, Gregory R. Pond, Karim Fizazi, Johann S. de Bono, Ethan M. Basch, Howard I. Scher, Matthew R. Smith  European Urology Oncology  DOI: 10.1016/j.euo.2018.11.006 Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 1 Survival according to risk group quartile. There was no significant difference in survival between the cabozantinib and control arms stratified by prognostic risk group quartile. European Urology Oncology DOI: (10.1016/j.euo.2018.11.006) Copyright © 2018 European Association of Urology Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com Inc. All rights reserved.